Abstract
Ceritinib is a new anaplastic lymphoma kinase (ALK) inhibitor that has shown greater potency in patients with advanced ALK-rearranged non-small cell lung cancer, including those who had disease progression in crizotinib treatment. Here we reported, after several months of ceritinib treatment, two patients with advanced ALK-rearranged pulmonary adenocarcinoma exhibited a spectrum of respiratory symptoms like cough and dyspnea, with significantly higher inflammatory indicators. Chest computed tomography (CT) showed multiple bilateral and peripheral lesions in lungs. The prior considerations taken into account were disease progression or infection. However, biopsies of the pulmonary nodules revealed features of granulomatous inflammation without definite cancer cells. We documented for the first time that ceritinib might be associated with pulmonary granulomatous inflammation, and clinicians should be alert to the possibility that the rare adverse event emerged during ceritinib treatment.
Introduction
In the management of advanced ALK-rearranged non-small cell lung cancer (NSCLC), second-generation ALK inhibitors like ceritinib have significantly improved outcomes for patients who progress on crizotinib. However, as targeted therapies evolve, so do the complexities of their side-effect profiles. Clinicians often encounter new pulmonary nodules during treatment, which are typically interpreted as either disease progression (acquired resistance) or opportunistic infection. This report identifies a third, rare possibility: drug-induced sarcoidosis-like reaction (DISR) manifesting as pulmonary granulomatous inflammation.
The Diagnostic Challenge: Imaging vs. Reality
The primary clinical challenge addressed in this study is the "diagnostic masquerade" presented by these inflammatory lesions. In the two cases observed at West China Hospital, patients presented with respiratory symptoms such as cough, dyspnea, and fever after approximately six months of ceritinib therapy.
Computed Tomography (CT) imaging revealed multiple bilateral masses and patchy shadows, findings that are classically associated with metastatic spread or treatment failure.
Methods and Diagnostic Workup
To differentiate between malignancy, infection, and inflammation, a multi-modal diagnostic approach was employed:
- Pathogen Screening: Extensive testing including sputum cultures, T-SPOT assays, and qPCR ruled out tuberculosis, bacterial, and fungal infections.
- Histopathology: The definitive diagnosis relied on invasive procedures. Fiberoptic bronchoscopy and CT-guided needle biopsies were performed to obtain tissue samples.
- Microscopic Examination: Specialized stains (PAS and silver hexamine) were used to evaluate the cellular architecture of the nodules.
Key Pathological Insights
The most critical finding was the absence of malignant cells in the new nodules. Instead, histopathological examination revealed chronic inflammatory cell infiltration and the formation of multinucleate giant cells, which are characteristic of granulomatous inflammation.
This discovery underscores that biopsy is non-negotiable when clinical symptoms or the timeline of lesion appearance do not align perfectly with expected patterns of cancer resistance.
Clinical Outcomes and Reversibility
A key takeaway from these cases is the reversibility of the condition. Unlike true disease progression, these inflammatory lesions responded to supportive care, temporary drug withdrawal, or glucocorticoid treatment. In one patient, shadows decreased significantly after a brief drug holiday; in the other, lesions were completely absorbed following glucocorticoid therapy.
Discussion and Limitations
This report represents the first documentation of ceritinib-associated pulmonary granulomatous inflammation. While the exact biological mechanism remains speculative, it is categorized as a DISR. The study is limited by its small sample size (n=2), making it difficult to estimate the general incidence of this adverse event. Future research is needed to determine if other ALK inhibitors share this profile and to develop non-invasive biomarkers that can distinguish inflammation from progression.
Conclusion
Clinicians should remain vigilant for rare adverse events like pulmonary granulomatous inflammation during ceritinib treatment. Recognizing this "mimicker" can prevent the premature discontinuation of an otherwise effective targeted therapy.
Summary updated